Literature DB >> 2190604

Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4.

J P Moore1.   

Abstract

Sensitive enzyme-linked immunosorbent assay-based methods are described for monitoring the binding of envelope glycoproteins from HIV-1 and HIV-2 to soluble CD4 (sCD4). Each of the assays has different properties suitable for different applications, but all can be used to characterize recombinant antigens and to screen for inhibitors of the gp120-CD4 interaction. Recombinant mammalian gp120 (Celltech) binds to sCD4 with high affinity (3 nM); this interaction is inhibited by sera from HIV-infected individuals and by specific monoclonal and polyclonal antibodies raised to a component of the CD4 binding site on gp120. The affinity for sCD4 of HIV-2 viral gp120 is shown to be approximately 25-fold lower than that of HIV-1 gp120 (viral or recombinant).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2190604     DOI: 10.1097/00002030-199004000-00003

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  63 in total

Review 1.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

2.  Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.

Authors:  C Y Kang; P Nara; S Chamat; V Caralli; T Ryskamp; N Haigwood; R Newman; H Köhler
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

3.  Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein.

Authors:  C Vita; E Drakopoulou; J Vizzavona; S Rochette; L Martin; A Ménez; C Roumestand; Y S Yang; L Ylisastigui; A Benjouad; J C Gluckman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

4.  Human immunodeficiency virus type 2 envelope glycoprotein binds to CD8 as well as to CD4 molecules on human T cells.

Authors:  H Kaneko; L P Neoh; N Takeda; H Akimoto; T Hishikawa; H Hashimoto; S Hirose; S Karaki; M Takiguchi; H Nakauchi; Y Kaneko; N Yamamoto; I Sekigawa
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  Simple assay to screen for inhibitors of interaction between the human immunodeficiency virus envelope glycoprotein and its cellular receptor, CD4.

Authors:  V Chams; T Idziorek; P J Maddon; D Klatzmann
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

6.  Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions.

Authors:  Qi Guo; Hsu-Tso Ho; Ira Dicker; Li Fan; Nannan Zhou; Jacques Friborg; Tao Wang; Brian V McAuliffe; Hwei-Gene Heidi Wang; Ronald E Rose; Hua Fang; Helen T Scarnati; David R Langley; Nicholas A Meanwell; Ralph Abraham; Richard J Colonno; Pin-Fang Lin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

8.  Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation.

Authors:  A C Andeweg; P Leeflang; A D Osterhaus; M L Bosch
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

9.  Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1.

Authors:  P J Klasse; J P Moore
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Viral multiplicity of attachment and its implications for human immunodeficiency virus therapies.

Authors:  J L Spouge
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.